Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Afoxolaner

Detailed information about Afoxolaner

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For the treatment of infestations caused by New World screwworm ( Cochliomyia hominivorax ) larvae (myiasis) in dogs and puppies.

What to watch for:

  • Death (1 reports)
  • wobbly/unsteady walking (1 reports)
  • very low energy (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • Death
  • wobbly/unsteady walking
  • very low energy

Most reported reactions:

  • Death (1 reports)
  • Unsteady walking (ataxia) (1 reports)
  • Tiredness (lethargy) (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:02 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 24, 2026, 11:05 AM UTC
Image coming soon
Afoxolaner

Afoxolaner

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Not available
Form: Chewable Tablets, Topical Solution
Identifiers:
NADA: 141406 NADA: 141554 NADA: 6685 NADA: 6686 NDC Package: 0010-2405-01 NDC Package: 0010-2405-02 NDC Package: 0010-2405-03 NDC Package: 0010-2407-01 NDC Package: 0010-2407-02 NDC Package: 0010-2407-03 NDC Package: 0010-2409-01 NDC Package: 0010-2409-02 NDC Package: 0010-2409-03 NDC Package: 0010-2411-01 NDC Package: 0010-2411-02 NDC Package: 0010-2411-03 NDC Package: 0010-4120-01 NDC Package: 0010-4120-02 NDC Package: 0010-4120-03 NDC Package: 0010-4121-01
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
26
Reported cases
14
Serious reports
1
Species represented
2
Grouped by Body System
Digestive (2) · Decreased appetite, Diarrhea Skin & allergy (3) · Itching, Hives, Hives (see also Skin) Neurologic (2) · Unsteady walking (ataxia), Tiredness (lethargy) Behavior (1) · Behavioral disorder (unspecified) Effectiveness (5) · Lack of efficacy (protozoa) - Giardia, Lack of efficacy (endoparasite) - tapeworm, Lack of efficacy (endoparasite) - roundworm NOS Other (13) · Shaking, Reluctant to move, Hiding
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Cat 1
Neurologic 1 Cat 0
Neurologic 1 Dog 0
Other 1 Cat 0
Other 1 Cat 0
Effectiveness 1 Dog 0
Effectiveness 1 Dog 0
Effectiveness 1 Dog 0

Species coverage: Dog (17) Cat (9)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Cat Non-serious - 1
Neurologic Dog Non-serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Effectiveness Dog Non-serious - 1
Effectiveness Dog Non-serious - 1
Effectiveness Dog Non-serious - 1
Effectiveness Dog Non-serious - 1
Skin & allergy Dog Non-serious - 1
Skin & allergy Dog Non-serious - 1
Other Cat Non-serious - 1
Digestive Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Effectiveness Dog Unknown - -
Other Dog Unknown - -
Other Cat Unknown - -
Other Cat Unknown - -
Skin & allergy Dog Unknown - -
Other Dog Unknown - -
Other Dog Unknown - -
Other Dog Unknown - -
Digestive Dog Unknown - -
Other Dog Unknown - -
Behavior Cat Unknown - -
Other Dog Unknown - -
Source metadata:

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)
  • No owner handouts linked yet.
Official label / PI (0)
  • No official label or package insert links yet.
SPL (4)
  • NexGard® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18427/NexGard%C2%AE
  • NexGard® COMBO · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18428/NexGard%C2%AE%20COMBO
  • NexGard® PLUS · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/14516/NexGard%C2%AE%20PLUS
  • NexGard® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2293/NexGard%C2%AE
FOI (12)
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 24, 2026, 11:05 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: NexGard® NexGard® COMBO NexGard® PLUS
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Chewable Tablets, Topical Solution • Oral, Topical
Applications: E 6685 • E 6686 • NADA 141-554 • NADA 141-406
Documents: 12 (FOI: 12) • SPL: 4 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 24 • Cat 9 • View
Case summaries: 12 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: B74.8 ICD10_CM: B88.1
Other filariases

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Death (1) Unsteady walking (ataxia) (1) Tiredness (lethargy) (1) Shaking (1) Reluctant to move (1) Lack of efficacy (protozoa) - Giardia (1) Lack of efficacy (endoparasite) - tapeworm (1) Lack of efficacy (endoparasite) - roundworm NOS (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141406 NADA: 141554 NADA: 6685 NADA: 6686 NDC Package: 0010-2405-01 NDC Package: 0010-2405-02 NDC Package: 0010-2405-03 NDC Package: 0010-2407-01 NDC Package: 0010-2407-02 NDC Package: 0010-2407-03 NDC Package: 0010-2409-01 NDC Package: 0010-2409-02 NDC Package: 0010-2409-03 NDC Package: 0010-2411-01 NDC Package: 0010-2411-02 NDC Package: 0010-2411-03 NDC Package: 0010-4120-01 NDC Package: 0010-4120-02 NDC Package: 0010-4120-03 NDC Package: 0010-4121-01 NDC Package: 0010-4121-02 NDC Package: 0010-4121-03 NDC Package: 0010-4260-01 NDC Package: 0010-4260-02
Package NDC Product NDC Form / Route Status
0010-2405-01 0010 -
0010-2405-02 0010 -
0010-2405-03 0010 -
0010-2407-01 0010 -
0010-2407-02 0010 -
0010-2407-03 0010 -
0010-2409-01 0010 -
0010-2409-02 0010 -
0010-2409-03 0010 -
0010-2411-01 0010 -
0010-2411-02 0010 -
0010-2411-03 0010 -
0010-4120-01 0010 -
0010-4120-02 0010 -
0010-4120-03 0010 -
0010-4121-01 0010 -
0010-4121-02 0010 -
0010-4121-03 0010 -
0010-4260-01 0010 -
0010-4260-02 0010 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 15 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy (ectoparasite) - tick NOS, Lethargy (see also Central nervous system depression in 'Neurological')… (Official, 2026-02-12)
  • usage: Kills adult fleas and is indicated for the treatment and prevention of flea infestations ( Ctenocephalides felis ), and the treatment and control of Ixodes sca… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
NexGard®
RX
Afoxolaner
Chewable Tablets • Oral
Label highlights
Official documents
Boehringer lngelheim Animal Health USA, Inc. E 6685 G Mar 2, 2026
NexGard® COMBO
RX
Eprinomectin Esafoxolaner Praziquantel
Topical Solution • Topical
Label highlights
Official documents
Boehringer lngelheim Animal Health USA, Inc. E 6686 G Mar 2, 2026
NexGard® PLUS
RX
Afoxolaner Moxidectin Pyrantel Pamoate
Chewable Tablets • Oral
Label highlights
Official documents
Boehringer lngelheim Animal Health USA, Inc. NADA 141-554 Approved Feb 2, 2026
NexGard®
RX
Afoxolaner
Chewable Tablets • Oral
Label highlights
Official documents
Boehringer lngelheim Animal Health USA, Inc. NADA 141-406 Approved Jan 14, 2025

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
Each chewable contains 11.3 mg, 28.3 mg, 68 mg, or 136 mg of afoxolaner
Dogs
Indication

For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies.

Dosage

NexGard® is given orally at the minimum dosage of 1.14 mg/lb (2.5 mg/kg). NexGard® should be used in conjunction with the mechanical removal of larvae (live and dead) remaining in the wound after treatment.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications
Esafoxolaner – 12 mg/mL, Eprinomectin – 4 mg/mL, Praziquantel – 83 mg/mL
Cats
Indication

For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens.

Dosage

NexGard® COMBO is dosed at a minimum of 0.055 mL/lb (0.12 mL/kg), which delivers a minimum dose of 0.65 mg/lb (1.44 mg/kg) esafoxolaner, 0.22 mg/lb (0.48 mg/kg) eprinomectin, and 4.53 mg/lb (9.98 mg/kg) praziquantel.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each chewable tablet contains 9.375 mg afoxolaner, 45 mcg moxidectin, and 18.75 mg pyrantel; 18.75 mg afoxolaner, 90 mcg moxidectin, and 37.5 mg pyrantel; 37.5 mg afoxolaner, 180 mcg moxidectin, and 75 mg pyrantel; 75 mg afoxolaner, 360 mcg moxidectin, and 150 mg pyrantel; or 150 mg afoxolaner, 720 mcg moxidectin, and 300 mg pyrantel.
Dogs
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult hookworm (Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria stenocephala) and roundworm (Toxocara canis and Toxascaris leonina) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of Ixodes scapularis (blacklegged tick), Rhipicephalus sanguineus (brown dog tick), Dermacentor variabilis (American dog tick), Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), and Haemaphysalis longicornis (longhorned tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater. For the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

Dosage

Administer orally once a month at the minimum dose of 1.14 mg/lb (2.5 mg/kg) afoxolaner, 5.45 mcg/lb (12 mcg/kg) moxidectin, and 2.27 mg/lb (5.0 mg/kg) pyrantel (as pamoate salt). For heartworm disease prevention, give once monthly for at least six months after last exposure to mosquitoes.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each chewable contains 11.3 mg, 28.3 mg, 68 mg, or 136 mg afoxolaner.
Dogs (Dogs and Puppies 8 Weeks of Age and Older)
Indication

Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis), and the treatment and control of Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Amblyomma americanum (lone star tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick) infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater, for 1 month; and for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

Dosage

NexGard® is given once a month at the minimum dosage of 1.14 mg/lb (2.5 mg/kg).

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    This supplement provides for the addition of the indication for the treatment and control of Amblyomma maculatum (Gulf Coast tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater.

  • Summary

    This supplement provides for the addition of the indication for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

  • Summary

    This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (longhorned tick) infestations in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater, for one month. This supplement also provides for the addition of label language regarding the results of a second flea field study and improvement of erythema, alopecia, papules, scales, crusts, and excoriation in dogs with flea infestations and signs of Flea Allergy Dermatitis following treatment with afoxolaner alone, as a direct result of eliminating fleas.

  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult hookworm (Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria stenocephala) and roundworm (Toxocara canis and Toxascaris leonina) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), Dermacentor variabilis (American dog tick), and Amblyomma americanum (lone star tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    This supplement provides for a new modified NexGard® formulation.

    This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (longhorned tick) infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater, for one month.

    This supplement also provides for the addition of label language regarding the improvement of erythema, alopecia, papules, scales, crusts, and excoriation in dogs with flea infestations and signs of Flea Allergy Dermatitis following treatment with NexGard®, as a direct result of eliminating fleas.

  • Summary

    This supplement provides for the addition of the indication for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

  • Summary
    The effect of the supplement is to provide for the treatment and control of Brown dog tick ( Rhipicephalus sanguineus) infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater, for one month.
  • Summary
    This supplement provides for the treatment and control of Black-legged tick (Ixodes scapularis) and Lone Star tick (Amblyomma americanum) infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater, for one month.
  • Summary
    The effect of the supplement is to add language to the Effectiveness section of the package insert from the flea speed of kill study.
  • Summary
    For the treatment and prevention of flea infestations (Ctenocephalides felis), and the treatment and control of American dog tick (Dermacentor variabilis) infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater, for 1 month.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

Kills adult fleas and is indicated for the treatment and prevention of flea infestations ( Ctenocephalides felis ), and the treatment and control of Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Amblyomma americanum (lone star tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick) infestations in dogs and puppies 8 weeks of age and older, weighing 4 pounds of body weight or greater, for 1 month; and for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks. For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult hookworm ( Ancylostoma caninum , Ancylostoma braziliense , and Uncinaria stenocephala ) and roundworm ( Toxocara canis and Toxascaris leonina ) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations ( Ctenocephalides felis ) and the treatment and control of Ixodes scapularis (blacklegged tick), Rhipicephalus sanguineus (brown dog tick), Dermacentor variabilis (American dog tick), Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), and Haemaphysalis longicornis (longhorned tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater. For the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Decreased appetite (1) • Dog Diarrhea • Dog

Showing top 5 for Digestive.

Skin & allergy
Itching (1) • Dog Hives (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Cat Tiredness (1) • Dog

Showing top 5 for Neurologic.

Behavior
Behavioral disorder • Cat

Showing top 5 for Behavior.

Effectiveness
Lack of efficacy (protozoa) - Giardia (1) • Dog Lack of efficacy (endoparasite) - tapeworm (1) • Dog Lack of efficacy (endoparasite) - roundworm NOS (1) • Dog Lack of efficacy (endoparasite) - hookworm (1) • Dog Lack of efficacy (bacteria) - Anaplasma • Dog

Showing top 5 for Effectiveness.

Other
Shaking (1) • Cat Reluctant to move (1) • Cat Hiding (1) • Cat Death (1) • Cat Administration error NOS (1) • Cat
Show more (8)
Inappropriate defecation • Dog Inappetence • Cat Hyperactivity • Cat Foaming at the mouth • Dog Elevated cholesterol • Dog Drug dose administration interval too short • Dog Decreased haematocrit • Dog Agitation • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Retriever - Golden, Unknown, 1 year, 26.76 kilogram • Drug: MSK, Unknown • Reactions: Lack of efficacy (endoparasite) - tapeworm • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-056118
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Unknown
  • Age: 1.00 Year
  • Weight: 26.760 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Lack of efficacy (endoparasite) - tapeworm
Outcomes: Outcome Unknown

Dog, Retriever - Golden, Unknown, 1 year, 20.86 kilogram • Drug: MSK, Unknown • Reactions: Lack of efficacy (endoparasite) - tapeworm • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-056116
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Unknown
  • Age: 1.00 Year
  • Weight: 20.860 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Lack of efficacy (endoparasite) - tapeworm
Outcomes: Outcome Unknown

Dog, Crossbred Canine/dog, Female, 12 year, 3.538 kilogram • Drug: MSK, Tablet, chewable, Unknown • Reactions: Hives, Tiredness (lethargy), Decreased appetite • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-055457
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 12.00 Year
  • Weight: 3.538 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet, chewable
Reactions Reported:
Hives Tiredness (lethargy) Decreased appetite
Outcomes: Recovered/Normal

Dog, Crossbred Canine/dog, Male, 8 year, 15.91 kilogram • Drug: MSK, Oral • Reactions: Lack of efficacy (endoparasite) - hookworm, Itching • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055786
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 8.00 Year
  • Weight: 15.910 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Lack of efficacy (endoparasite) - hookworm Itching
Outcomes: Outcome Unknown

Dog, Retriever - Labrador, Female, 8 year, 31.751 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal, Frequency: 30 per day • Reactions: Lack of efficacy (endoparasite) - roundworm NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055413
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 8.00 Year
  • Weight: 31.751 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 1 tablet per animal
  • Frequency: 30 per day
Reactions Reported:
Lack of efficacy (endoparasite) - roundworm NOS
Outcomes: Ongoing

Dog, Retriever - Labrador, Male, 7 year, 33.112 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Lack of efficacy (endoparasite) - tapeworm • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055716
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 7.00 Year
  • Weight: 33.112 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 1 tablet per animal
Reactions Reported:
Lack of efficacy (endoparasite) - tapeworm
Outcomes: Outcome Unknown

Dog, Doberman Pinscher, Male, 5 month, 21.863 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 dose per animal • Reactions: Lack of efficacy (endoparasite) - hookworm, Lack of efficacy (protozoa) - Giardia • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055419
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 5.00 Month
  • Weight: 21.863 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 1 dose per animal
Reactions Reported:
Lack of efficacy (endoparasite) - hookworm Lack of efficacy (protozoa) - Giardia
Outcomes: Ongoing

Cat, Domestic Longhair, Female, 8 year, 6.577 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 0.50 tablet per animal • Reactions: Hiding, Administration error NOS • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-050688
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 8.00 Year
  • Weight: 6.577 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 0.50 tablet per animal
Reactions Reported:
Hiding Administration error NOS
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.